Hlib Chabaniuk

Cullinan Therapeutics posts Q2 2026 financial results and updates on T cell engager pipeline milestones

Cullinan Therapeutics posts Q2 2026 financial results and updates on T cell engager pipeline milestones
Cullinan Q2 2026 results, pipeline

Cullinan Therapeutics reported its corporate update and financial results for the second quarter of 2026, sharing details on business performance and developments in its T cell engager pipeline.

The company outlined upcoming operational milestones and growth initiatives, encouraging stakeholders to review additional information through its latest presentation.

Earlier this year, Cullinan Therapeutics advanced its CLN-049 therapy to Phase 2 for relapsed and refractory AML following positive FDA feedback, according to company disclosures. The company has also supported LGBTQIA biotech professionals through sponsorship of the OUTbio Boston event, as noted in previous reports. These efforts reflect Cullinan's continued activity on pipeline development and industry engagement.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.